These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3470 related items for PubMed ID: 26188279

  • 41. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
    Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Rasp KH, Illing B, Döhner H, Döhner K, Schittenhelm MM.
    Mol Cancer; 2013 May 24; 12():46. PubMed ID: 23705826
    [Abstract] [Full Text] [Related]

  • 42. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.
    Leung E, Kim JE, Rewcastle GW, Finlay GJ, Baguley BC.
    Cancer Biol Ther; 2011 Jun 01; 11(11):938-46. PubMed ID: 21464613
    [Abstract] [Full Text] [Related]

  • 43. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
    Santiskulvong C, Konecny GE, Fekete M, Chen KY, Karam A, Mulholland D, Eng C, Wu H, Song M, Dorigo O.
    Clin Cancer Res; 2011 Apr 15; 17(8):2373-84. PubMed ID: 21372221
    [Abstract] [Full Text] [Related]

  • 44. The dual PI3K/mTOR inhibitor NVP-BEZ235 prevents epithelial-mesenchymal transition induced by hypoxia and TGF-β1.
    Lin G, Gai R, Chen Z, Wang Y, Liao S, Dong R, Zhu H, Gu Y, He Q, Yang B.
    Eur J Pharmacol; 2014 Apr 15; 729():45-53. PubMed ID: 24561043
    [Abstract] [Full Text] [Related]

  • 45. Levels of p27 sensitize to dual PI3K/mTOR inhibition.
    Lee M, Theodoropoulou M, Graw J, Roncaroli F, Zatelli MC, Pellegata NS.
    Mol Cancer Ther; 2011 Aug 15; 10(8):1450-9. PubMed ID: 21646547
    [Abstract] [Full Text] [Related]

  • 46. NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells.
    Moon du G, Lee SE, Oh MM, Lee SC, Jeong SJ, Hong SK, Yoon CY, Byun SS, Park HS, Cheon J.
    Int J Oncol; 2014 Sep 15; 45(3):1027-35. PubMed ID: 24969552
    [Abstract] [Full Text] [Related]

  • 47. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E, Troiani T, D'Aiuto E, Morgillo F, Vitagliano D, Capasso A, Costantino S, Ciuffreda LP, Merolla F, Vecchione L, De Vriendt V, Tejpar S, Nappi A, Sforza V, Martini G, Berrino L, De Palma R, Ciardiello F.
    Int J Cancer; 2013 Nov 15; 133(9):2089-101. PubMed ID: 23629727
    [Abstract] [Full Text] [Related]

  • 48. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma.
    Yang F, Qian XJ, Qin W, Deng R, Wu XQ, Qin J, Feng GK, Zhu XF.
    PLoS One; 2013 Nov 15; 8(3):e59879. PubMed ID: 23533654
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.
    Oishi T, Itamochi H, Kudoh A, Nonaka M, Kato M, Nishimura M, Oumi N, Sato S, Naniwa J, Sato S, Shimada M, Kigawa J, Harada T.
    Oncol Rep; 2014 Aug 15; 32(2):553-8. PubMed ID: 24927217
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
    Okabe S, Tauchi T, Tanaka Y, Kitahara T, Kimura S, Maekawa T, Ohyashiki K.
    Cancer Biol Ther; 2014 Feb 15; 15(2):207-15. PubMed ID: 24100660
    [Abstract] [Full Text] [Related]

  • 55. Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability.
    Seo BR, Min KJ, Cho IJ, Kim SC, Kwon TK.
    PLoS One; 2014 Feb 15; 9(4):e95588. PubMed ID: 24743574
    [Abstract] [Full Text] [Related]

  • 56. Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line.
    Ayub A, Yip WK, Seow HF.
    Biomed Pharmacother; 2015 Oct 15; 75():40-50. PubMed ID: 26463630
    [Abstract] [Full Text] [Related]

  • 57. Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.
    Jin Z, Qing K, Ouyang Y, Liu Z, Wang W, Li X, Xu Z, Li J.
    J Exp Clin Cancer Res; 2016 Mar 24; 35():52. PubMed ID: 27009084
    [Abstract] [Full Text] [Related]

  • 58. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
    Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, Pannetier M, Willems L, Park S, Macone A, Maira SM, Ifrah N, Dreyfus F, Herault O, Lacombe C, Mayeux P, Bouscary D.
    Clin Cancer Res; 2010 Nov 15; 16(22):5424-35. PubMed ID: 20884625
    [Abstract] [Full Text] [Related]

  • 59. Abrogation of Autophagy by Chloroquine Alone or in Combination with mTOR Inhibitors Induces Apoptosis in Neuroendocrine Tumor Cells.
    Avniel-Polak S, Leibowitz G, Riahi Y, Glaser B, Gross DJ, Grozinsky-Glasberg S.
    Neuroendocrinology; 2016 Nov 15; 103(6):724-37. PubMed ID: 26619207
    [Abstract] [Full Text] [Related]

  • 60. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer.
    Chen YH, Wei MF, Wang CW, Lee HW, Pan SL, Gao M, Kuo SH, Cheng AL, Teng CM.
    Cancer Lett; 2015 Feb 28; 357(2):582-90. PubMed ID: 25497009
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 174.